Stocktoria
Protalix BioTherapeutics, Inc. PLX
NYSE American · XASE · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2010-09-06
Protalix BioTherapeutics, Inc. financials (annual, from 10-K)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $52.7M | $53.4M | $65.5M | $47.6M | $38.4M | $62.9M | $54.7M | $34.2M | $21.1M | $9.2M |
| Gross profit | — | — | — | — | — | — | — | — | $4.0M | $801,000 |
| R&D expense | $19.6M | $13.0M | $17.1M | $29.3M | $29.7M | $38.2M | $44.6M | $33.3M | $32.2M | $30.4M |
| SG&A expense | $11.7M | $12.2M | $15.0M | $11.7M | $12.7M | $11.1M | $9.9M | $10.9M | $11.5M | $9.4M |
| Operating income | -$5.5M | $3.9M | $10.5M | -$13.0M | -$20.5M | $2.7M | -$10.7M | -$19.3M | -$34.5M | -$33.2M |
| Income tax | $996,000 | $1.2M | $254,000 | $530,000 | — | — | — | — | — | — |
| Net income | -$6.6M | $2.9M | $8.3M | -$14.9M | -$27.6M | -$6.5M | -$18.3M | -$26.5M | -$83.4M | -$29.4M |
| EPS (diluted) | $-0.08 | $0.04 | $0.09 | $-0.31 | $-0.62 | $-0.22 | $-1.23 | — | — | — |
| Operating cash flow | -$12.0M | $8.7M | -$1.3M | -$25.0M | -$10.3M | -$26.1M | -$19.4M | -$7.7M | -$10.0M | -$32.1M |
| Free cash flow | -$13.6M | $7.4M | -$2.5M | -$25.6M | -$11.7M | -$26.8M | -$20.0M | -$8.4M | -$11.0M | -$32.9M |
| Cash & equivalents | $14.7M | $19.8M | $23.6M | $17.1M | $39.0M | $18.3M | $17.8M | $37.8M | $51.2M | $63.3M |
| Inventory | $25.7M | $21.2M | $19.0M | $16.8M | $18.0M | $13.1M | $8.2M | $8.6M | $7.8M | $5.2M |
| Total assets | $82.3M | $73.4M | $84.4M | $55.8M | $73.7M | $67.9M | $45.4M | $61.1M | $72.2M | $82.2M |
| Total liabilities | $34.1M | $30.2M | $50.9M | $66.4M | $79.7M | $95.0M | $115.7M | $114.0M | $101.7M | $92.2M |
| Shareholders' equity | $48.2M | $43.2M | $33.6M | -$10.6M | -$6.0M | -$27.0M | -$70.3M | -$52.9M | -$29.5M | -$10.0M |
Growth · year-over-year · Revenue CAGR 21.4%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -1.2% | -18.5% | +37.5% | +24.2% | -39.0% | +15.0% | +59.7% | +62.4% | +129.1% | +110.8% |
| Net income growth | -325.2% | -64.7% | — | — | — | — | — | — | — | -150.6% |
| EPS growth | -300.0% | -55.6% | — | — | — | — | — | — | — | — |
| Free cash flow growth | -284.4% | — | — | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: SEC EDGAR filings · CIK 0001006281 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.